Epidermal growth factor reduces ischemia-reperfusion injury in rat small intestine

Xavier Villa, John W. Kuluz, Charles L. Schleien, John F. Thompson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: To measure the effect of pre-ischemic administration of intraluminal epidermal growth factor on the changes in intestinal permeability induced by 30 mins of superior mesenteric artery occlusion, followed by 2 hrs of reperfusion. Design: Prospective, randomized, placebo-controlled experimental study. Setting: University basic science research laboratory. Subjects: Healthy, young, adult, male Sprague-Dawley rats. Interventions: A 10-cm segment of small intestine was isolated and studied in situ in rats that were anesthetized with fentanyl and mechanically ventilated. Intestinal ischemia-reperfusion injury was induced by temporary occlusion of the superior mesenteric artery for 30 mins, followed by 2 hrs of reperfusion. Three groups were studied: time controls with a sham operation, saline-treated ischemia-reperfusion, and epidermal growth factor-treated ischemia-reperfusion. Epidermal growth factor, 100 ng/min, was infused intraluminally, beginning 30 mins before and continued until 40 mins after ischemia. Measurements and Main Results: Intestinal permeability was measured for each 10-min time period by using chromium-labeled EDTA. Histopathologic injury was assessed by light microscopy. After superior mesenteric artery occlusion, intestinal permeability increased approximately ten-fold and was sustained for 2 hrs of reperfusion in saline-treated rats. Pretreatment with epidermal growth factor significantly reduced the permeability changes during reperfusion by >60% compared with saline-treated animals (p < .05). Histopathologic sections revealed apparently more extensive loss of epithelial cells and mucosal disruption in saline-treated intestine compared with epidermal growth factor-treated intestine. Conclusion: Pre-ischemic administration of intraluminal epidermal growth factor significantly protects against intestinal ischemia-reperfusion injury.

Original languageEnglish (US)
Pages (from-to)1576-1580
Number of pages5
JournalCritical Care Medicine
Volume30
Issue number7
StatePublished - 2002
Externally publishedYes

Fingerprint

Reperfusion Injury
Epidermal Growth Factor
Small Intestine
Reperfusion
Superior Mesenteric Artery
Permeability
Ischemia
Intestines
antineoplaston A10
Fentanyl
Edetic Acid
Sprague Dawley Rats
Young Adult
Microscopy
Healthy Volunteers
Epithelial Cells
Placebos
Light
Wounds and Injuries
Research

Keywords

  • Enteropathy
  • Epidermal growth factor
  • Epithelium
  • Gut
  • Intestinal mucosa
  • Jejunum
  • Mucus
  • Multiple organ dysfunction syndrome
  • Permeability

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Epidermal growth factor reduces ischemia-reperfusion injury in rat small intestine. / Villa, Xavier; Kuluz, John W.; Schleien, Charles L.; Thompson, John F.

In: Critical Care Medicine, Vol. 30, No. 7, 2002, p. 1576-1580.

Research output: Contribution to journalArticle

Villa, Xavier ; Kuluz, John W. ; Schleien, Charles L. ; Thompson, John F. / Epidermal growth factor reduces ischemia-reperfusion injury in rat small intestine. In: Critical Care Medicine. 2002 ; Vol. 30, No. 7. pp. 1576-1580.
@article{43a2fb5d570f4cb69488da6e56392caa,
title = "Epidermal growth factor reduces ischemia-reperfusion injury in rat small intestine",
abstract = "Objective: To measure the effect of pre-ischemic administration of intraluminal epidermal growth factor on the changes in intestinal permeability induced by 30 mins of superior mesenteric artery occlusion, followed by 2 hrs of reperfusion. Design: Prospective, randomized, placebo-controlled experimental study. Setting: University basic science research laboratory. Subjects: Healthy, young, adult, male Sprague-Dawley rats. Interventions: A 10-cm segment of small intestine was isolated and studied in situ in rats that were anesthetized with fentanyl and mechanically ventilated. Intestinal ischemia-reperfusion injury was induced by temporary occlusion of the superior mesenteric artery for 30 mins, followed by 2 hrs of reperfusion. Three groups were studied: time controls with a sham operation, saline-treated ischemia-reperfusion, and epidermal growth factor-treated ischemia-reperfusion. Epidermal growth factor, 100 ng/min, was infused intraluminally, beginning 30 mins before and continued until 40 mins after ischemia. Measurements and Main Results: Intestinal permeability was measured for each 10-min time period by using chromium-labeled EDTA. Histopathologic injury was assessed by light microscopy. After superior mesenteric artery occlusion, intestinal permeability increased approximately ten-fold and was sustained for 2 hrs of reperfusion in saline-treated rats. Pretreatment with epidermal growth factor significantly reduced the permeability changes during reperfusion by >60{\%} compared with saline-treated animals (p < .05). Histopathologic sections revealed apparently more extensive loss of epithelial cells and mucosal disruption in saline-treated intestine compared with epidermal growth factor-treated intestine. Conclusion: Pre-ischemic administration of intraluminal epidermal growth factor significantly protects against intestinal ischemia-reperfusion injury.",
keywords = "Enteropathy, Epidermal growth factor, Epithelium, Gut, Intestinal mucosa, Jejunum, Mucus, Multiple organ dysfunction syndrome, Permeability",
author = "Xavier Villa and Kuluz, {John W.} and Schleien, {Charles L.} and Thompson, {John F.}",
year = "2002",
language = "English (US)",
volume = "30",
pages = "1576--1580",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Epidermal growth factor reduces ischemia-reperfusion injury in rat small intestine

AU - Villa, Xavier

AU - Kuluz, John W.

AU - Schleien, Charles L.

AU - Thompson, John F.

PY - 2002

Y1 - 2002

N2 - Objective: To measure the effect of pre-ischemic administration of intraluminal epidermal growth factor on the changes in intestinal permeability induced by 30 mins of superior mesenteric artery occlusion, followed by 2 hrs of reperfusion. Design: Prospective, randomized, placebo-controlled experimental study. Setting: University basic science research laboratory. Subjects: Healthy, young, adult, male Sprague-Dawley rats. Interventions: A 10-cm segment of small intestine was isolated and studied in situ in rats that were anesthetized with fentanyl and mechanically ventilated. Intestinal ischemia-reperfusion injury was induced by temporary occlusion of the superior mesenteric artery for 30 mins, followed by 2 hrs of reperfusion. Three groups were studied: time controls with a sham operation, saline-treated ischemia-reperfusion, and epidermal growth factor-treated ischemia-reperfusion. Epidermal growth factor, 100 ng/min, was infused intraluminally, beginning 30 mins before and continued until 40 mins after ischemia. Measurements and Main Results: Intestinal permeability was measured for each 10-min time period by using chromium-labeled EDTA. Histopathologic injury was assessed by light microscopy. After superior mesenteric artery occlusion, intestinal permeability increased approximately ten-fold and was sustained for 2 hrs of reperfusion in saline-treated rats. Pretreatment with epidermal growth factor significantly reduced the permeability changes during reperfusion by >60% compared with saline-treated animals (p < .05). Histopathologic sections revealed apparently more extensive loss of epithelial cells and mucosal disruption in saline-treated intestine compared with epidermal growth factor-treated intestine. Conclusion: Pre-ischemic administration of intraluminal epidermal growth factor significantly protects against intestinal ischemia-reperfusion injury.

AB - Objective: To measure the effect of pre-ischemic administration of intraluminal epidermal growth factor on the changes in intestinal permeability induced by 30 mins of superior mesenteric artery occlusion, followed by 2 hrs of reperfusion. Design: Prospective, randomized, placebo-controlled experimental study. Setting: University basic science research laboratory. Subjects: Healthy, young, adult, male Sprague-Dawley rats. Interventions: A 10-cm segment of small intestine was isolated and studied in situ in rats that were anesthetized with fentanyl and mechanically ventilated. Intestinal ischemia-reperfusion injury was induced by temporary occlusion of the superior mesenteric artery for 30 mins, followed by 2 hrs of reperfusion. Three groups were studied: time controls with a sham operation, saline-treated ischemia-reperfusion, and epidermal growth factor-treated ischemia-reperfusion. Epidermal growth factor, 100 ng/min, was infused intraluminally, beginning 30 mins before and continued until 40 mins after ischemia. Measurements and Main Results: Intestinal permeability was measured for each 10-min time period by using chromium-labeled EDTA. Histopathologic injury was assessed by light microscopy. After superior mesenteric artery occlusion, intestinal permeability increased approximately ten-fold and was sustained for 2 hrs of reperfusion in saline-treated rats. Pretreatment with epidermal growth factor significantly reduced the permeability changes during reperfusion by >60% compared with saline-treated animals (p < .05). Histopathologic sections revealed apparently more extensive loss of epithelial cells and mucosal disruption in saline-treated intestine compared with epidermal growth factor-treated intestine. Conclusion: Pre-ischemic administration of intraluminal epidermal growth factor significantly protects against intestinal ischemia-reperfusion injury.

KW - Enteropathy

KW - Epidermal growth factor

KW - Epithelium

KW - Gut

KW - Intestinal mucosa

KW - Jejunum

KW - Mucus

KW - Multiple organ dysfunction syndrome

KW - Permeability

UR - http://www.scopus.com/inward/record.url?scp=0036314651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036314651&partnerID=8YFLogxK

M3 - Article

C2 - 12130982

AN - SCOPUS:0036314651

VL - 30

SP - 1576

EP - 1580

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 7

ER -